Even if future studies confirm a clinical benefit, widespread implementation is likely to be challenging due to practical limitations, including supply chain and infrastructural constraints, the complexity of individualised dose planning, and dose-limiting toxicities such as xerostomia in PSMA-targeted RLT. Here, FOLH1 is linked to xerostomia.